BRILINTA can lead to fewer CV events for STEMI patients compared to clopidogrel, allowing a growing support for BRILINTA® (ticagrelor) [package insert]. Find out about the BRILINTA® (ticagrelor) mechanism of action. BRILINTA is the first-and-only ;(3) BRILINTA® (ticagrelor) [package insert]. Patient Information Leaflet. Package leaflet: Information for the user. Brilique 90 mg film-coated tablets ticagrelor. Read all of this leaflet carefully before you start .
|Published (Last):||13 June 2004|
|PDF File Size:||9.74 Mb|
|ePub File Size:||19.20 Mb|
|Price:||Free* [*Free Regsitration Required]|
Evolving Treatment Paradigm in ACS | BRILINTA® (ticagrelor) tablets
After one year administer 60 mg twice daily. Bradyarrhythmias including AV block have been reported in the post-marketing setting. I recently had a heart attack, but I am not a victim.
Tell your doctor if you take other medicines that contain aspirin. Subject to eligibility rules ; restrictions apply.
Strong inducers substantially reduce ticagrelor exposure and so decrease the efficacy of ticagrelor As with other oral P2Y 12 inhibitors, co-administration of opioid agonists delay and reduce the absorption of ticagrelor.
People who are treated with a stent, and stop taking BRILINTA too soon, have a higher risk of getting a blood clot in the stent, having a heart attack, or dying. BRILINTA is used with aspirin to lower your chance of having another serious problem with your heart or blood vessels such as heart attack, stroke, or blood clots in your stent if you received one. Plavix is indicated to reduce the rate of myocardial infarction and stroke For in patients with acute ST-elevation myocardial infarction STEMI who are to be managed medically.
The optimal duration of Plavix therapy is unknown. For at least the first 12 months following ACS, it is superior to clopidogrel. Plavix has been shown to decrease the rate of packxge combined endpoint pac,age cardiovascular death, myocardial infarction MIor stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.
BRILINTA Mechanism of Action (MOA) – BRILINTA® (ticagrelor) tablets | For HCPs
Instances of serious bleeding, such as internal bleeding, may require blood transfusions or surgery. Plavix is a registered trademark of sanofi-aventis. Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re infarction, or stroke. Strong inhibitors substantially increase ticagrelor exposure and so increase the risk of adverse events.
Call your doctor if you have new or unexpected shortness of breath or any side effect that bothers you or that does not go away.
A CHANGING TREATMENT PARADIGM
You may report side effects related to AstraZeneca products by clicking here. Plavix should be administered in conjunction with aspirin.
Do not take new medicines that contain aspirin. You may report side effects related to AstraZeneca products by clicking here.
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Administer 90 mg twice daily during the first year after an ACS event. Your doctor can decide what treatment is needed. Briinta will also take longer than usual to stop.
BRILINTA MECHANISM OF ACTION
Brilinra benefit for patients who undergo primary percutaneous coronary intervention is unknown. These can be fatal. For complete information on changes to the Plavix PI, go to www.